Historic Partnership between the Weizmann Institute of Science and Institut Curie
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.
Collaborative research programs
This partnership will extend to many disciplines, including physics,
chemistry, cellular biology, epigenetics, genetics, immunology and
single cell approaches, imagery and data collection. The complementarity
of the research between the various groups at Institut Curie and at the
Weizmann Institute has been recognized in particular at the occasion of
joint scientific workshops held regularly alternatively in Paris and
Rehovot. Each research program will be organized around a pair of
researchers with a scientist from Institut Curie and a scientist from
the Weizmann Institute of Sciences, who will receive support on the
annual basis. This partnership also includes exchanges of scientists and
a Curie-Weizmann symposium organized every two years, with alternate
locations in Rehovot, Israel, and in Paris, which will be focused on one
of the subjects of research cooperation.
To finance the start of this cooperation, Institut Curie and the Weizmann Institute of Sciences will finance this research program for €200,000 each, and will organize a joint fundraiser with philanthropists and corporate sponsors.
Projects with high hopes
There are numerous common interests between the two Institutes. They can range from the description of defects in cell nuclei to the mechanics of cell migration, or the behavior of neural networks. A few examples of exciting ongoing projects are highlighted below.
During his sabbatical visit at Institut Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in several projects ranging from cell migration to collective cell behaviors and neuron growth. For instance, he developed a theory in collaboration with Raphael Voituriez (Sorbonne University), which explains the observations of the team of Matthieu Piel (Institut Curie) on the links between persistence and speed of migrating cells. This theory gave rise to collaborative developments between these three teams to predict important aspects of the migratory behavior of immune cells.
He also collaborated with Pascal Silberzan at Institut Curie to understand the behavior of cells packed at very high density on a surface. This joint work combining experiments and theory, has highlighted the importance of an intrinsic biological ageing of the cell population. This project has helped understanding how cells can come to an arrest while maintaining a capacity to respond to external perturbations such as an injury.
Elisha Moses (Weizmann Institute) has a longstanding interaction with the group of Professor Jean-Louis Viovy (Institut Curie), now headed by Stéphanie Descroix, on the applications of microfluidic devices to the study of living neuronal networks. He spent three months in Paris, during which he and Dr. Catherine Villard of the Descroix lab developed an optogenetic assay for guiding axonal growth. This work has the potential for controlling growth of neurons and of neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two talented researchers who were working on the project as students, have now graduated and branched off into very interesting conceptual and practical applications of this approach.
An important complementarity
The two institutions are both highly complementary and display many mutually common attributes.
Institut Curie is the premier research center in France conducting cancer research, including all facets of carcinogenesis. Its research center brings together 1,200 researchers working in 12 joint research units organized in four areas based on natural scientific interactions and robust medical potentiality. A strong advocate of international cooperation , it welcomes more than 80 nationalities. Equipped with advanced technology platforms, it is an important resource for researchers around the world. Institut Curie is also a state-of-the-art hospital complex that provides care and support for all cancer types and welcomes more than 50,000 patients each year. It has developed particularly innovative treatments directly from the work of its research center. Institut Curie also trains students in science and cancer research with the goal of increasing the knowledge about the topic.
The Weizmann Institute of Science is among the ten premier institutes of fundamental research in the world: 2,500 scientists work on its campus in Rehovot in the complementary fields of mathematics and computer science, physics, biology, chemistry, and biochemistry. The Weizmann Institute of Science has a long history of research and discoveries rooted in a mission of advancement of science for the benefit of humanity; cancer research accounts for 40% of the total budget of the Institute, which shapes and hosts a large part of the leadership in Israel and contributes to the advancement and understanding of scientific issues among all audiences.
Both institutions have powerful means of technology transfer that leverage the discoveries of their labs for the benefit of patients, whether through the creation of medications, medical devices or other technologies.
A shared vision of science
Science at the service of people - this is the best way to describe the credo of the two institutes, both of which were founded upon great personalities who have made an important mark in the history of the world.
Chaim Weizmann, chemist and author of many discoveries and publications, is the founder of the Weizmann Institute, and was the first president of the State of Israel between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the Radium Institute in 1909. The first female professor and holder of a chair position at the Sorbonne, the first woman to win two Nobel prizes and be enshrined at the Pantheon in Paris on her own merit. In many ways, these two scientists have had a remarkable journey.
But beyond these prestigious founders, the two institutes share the same vision of science, at the service of people and driven by strong values, the same curiosity for discovery and knowledge at the service of human health.
The Weizmann Institute of Science and Institut Curie also share a common belief that international collaborations in the field of institut-curie.org science and the exchange of ideas across interdisciplinary boundaries can accelerate progress to the benefit of humanity.
It is this common ground which today enables this collaboration to take root and which will tomorrow allow us to multiply efforts and as a result enjoy major new discoveries.
+33 (0)1 56 24 55 53
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Immersion Signs Agreement With TDK Electronics Bringing Haptics Design and Marketing to PowerHap Piezo Actuators24.4.2019 15:30:00 EEST | Tiedote
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, announced that it has signed an agreement with TDK Corp. (TSE:6762) subsidiary TDK Electronics for the design and marketing of haptic feedback for TDK PowerHap™ piezo actuators. Under the agreement, Immersion will include TDK’s actuators in reference designs for automotive, industrial and other markets. Immersion will also certify the components for use with its software products. This will enable TDK’s customers in a wide variety of markets to rapidly implement cutting-edge haptic solutions with its high-performance actuators. With 25 years in the field of touch technology, Immersion brings together the art of design and the precise science behind haptic feedback in actuators and ICs. The company connects the haptic ecosystem through the certification of haptic components, helping partners like TDK and their customers maintain consistency and high-fidelity haptic experiences across de
Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities24.4.2019 15:30:00 EEST | Tiedote
Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta® (axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor (TCR) cell therapies being evaluated in solid tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005257/en/ “This new facility in Frederick County builds on our substantial technical capabilities and rapid progress in making personalized CAR T and TCR cell therapies for people with cancer. As we advance our industry-leading cell therapy pipeline and seek to help a growing number of people with cancer, expanding and investing in our manufacturing capabilities is essentia
SugarCRM Announces Game-Changing Product Enhancements to Accelerate Growth, Improve Business Performance and Deliver Exceptional Customer Experiences24.4.2019 15:00:00 EEST | Tiedote
SugarCRM Inc.®, the company that helps organizations build better business relationships, today announced several new platform capabilities to help companies to accelerate their business growth. These new capabilities will enable them to resolve customer issues quickly, collaborate more effectively, make faster and more informed decisions about their customers, eliminate time-consuming manual processes, expand real-time mobile access to critical customer information – and do all of this on the new, blazing-fast Sugar 9 platform. “With these significant enhancements, our customers can now collaborate and communicate more effectively, know more about their customers to quickly make better decisions and confidently transact more business with faster quotes, more automation and rock-solid SOC 2 compliance. Most importantly, we have boosted system performance to new heights, enabling customers to process up to 70% more transactions without investing in new hardware,” says Rich Green, chief
USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations24.4.2019 15:00:00 EEST | Tiedote
Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$90 million agreement to co-create local deep tech start-ups in the healthcare and life sciences sector. This agreement, is the latest in a series of venture co-creation (VCC) agreements signed by A*ccelerate to strengthen the start-up ecosystem in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005535/en/ (Photo: Business Wire) Through this agreement, Aptorum Group and A*ccelerate are looking at creating up to 20 deep tech ventures in Singapore over the next five years. These enterprises will leverage technologies co-developed by A*STAR research institutes and Aptorum Group. As part of this agreement, the parties involved will also support the start-ups’ growth through actively nurturing the entrepreneurs. This w
IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 13:18:00 EEST | Tiedote
The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 13:00:00 EEST | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme